Subsequent Events	9 Months Ended
Sep. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events In September 2016, we received a notice from Shire of Shire’s termination of the Development, Commercialization and License Agreement, or the Original License Agreement (the “Notice of Termination”) stating that the effective date of termination (the “Termination Date”) would have been the earliest date to be demonstrated or agreed upon in accordance with the provisions of the Original License Agreement. Under the terms of the Original License Agreement, the Termination Date would have been between 30 days and six months from the date of receipt of the Notice of Termination. At the Termination Date, we would have regained worldwide rights for the development and commercialization of pacritinib and the Company and Shire would have had certain rights and obligations as set forth in the Original License Agreement. In September 2016, we entered into a letter agreement amending the Original License Agreement by providing that if we were unable to negotiate and execute within 30 days (the “Letter Agreement Deadline”) a definitive agreement reflecting the terms contained within the non-binding term sheet agreed to between us and Baxalta on September 19, 2016 regarding the termination of the Original License Agreement and the return of the asset, then for purposes of computing any applicable termination periods and deadlines under Section 15.2 of the Original License Agreement, September 13, 2016 would have been deemed the effective date of the Notice of Termination. In October 2016, we and Baxalta entered into a letter agreement extending the Letter Agreement Deadline to 5:00pm Eastern Time on October 21, 2016. Prior to the deadline, in October 2016, we entered into the Asset Return and Termination Agreement (the “Termination Agreement”) with Baxalta. Pursuant to the Termination Agreement, the Original License Agreement was terminated in its entirety (other than certain customary provisions that survive termination, including those pertaining to confidentiality and indemnification), the Original License Agreement has no further force or effect, and all rights and obligations of the Company and Baxalta under the Original License Agreement were terminated. For additional information relating to the Termination Agreement, see Part I, Item 2, “License Agreements and Milestone Activities - Shire”. In October 2016, we announced that James A. Bianco, M.D. retired from his position as president and chief executive officer. At the request of the Board of Directors, Richard Love, a director of the Company since 2007, was appointed to serve as interim president and chief executive officer. In connection with Dr. Bianco’s separation, we recorded $5.6 million in severance related costs which were recorded in selling, general and administrative expenses in the Statement of Operations for the three and nine months ended September 30, 2016. Concurrently with Dr. Bianco’s separation, we entered into a Consulting Agreement, (the “Bianco Consulting Agreement”) and an Effective Date Option Agreement, (the “Bianco Effective Date Option Agreement”) with Dr. Bianco. The Bianco Consulting Agreement provides for exclusive consulting services from Dr. Bianco for 12 months following his separation for a total consulting fee of $0.5 million to be paid in two installments. The Bianco Effective Date Option Agreement granted Dr. Bianco a stock option award covering 6,539,290 shares of our common stock, with 4,539,290 of the shares subject to the option at a per share exercise price of $0.3743 and 2,000,000 of the shares subject to the option at a per share exercise price of $1.10. Each of Dr. Bianco’s outstanding stock options granted by us are fully vested and Dr. Bianco will generally have up to two years from the date of his separation to exercise his vested stock options.

Subsequent Events

In September 2016, we received a notice from Shire of Shire’s termination of the Development, Commercialization and License Agreement, or the Original License Agreement (the “Notice of Termination”) stating that the effective date of termination (the “Termination Date”) would have been the earliest date to be demonstrated or agreed upon in accordance with the provisions of the Original License Agreement. Under the terms of the Original License Agreement, the Termination Date would have been between 30 days and six months from the date of receipt of the Notice of Termination. At the Termination Date, we would have regained worldwide rights for the development and commercialization of pacritinib and the Company and Shire would have had certain rights and obligations as set forth in the Original License Agreement. In September 2016, we entered into a letter agreement amending the Original License Agreement by providing that if we were unable to negotiate and execute within 30 days (the “Letter Agreement Deadline”) a definitive agreement reflecting the terms contained within the non-binding term sheet agreed to between us and Baxalta on September 19, 2016 regarding the termination of the Original License Agreement and the return of the asset, then for purposes of computing any applicable termination periods and deadlines under Section 15.2 of the Original License Agreement, September 13, 2016 would have been deemed the effective date of the Notice of Termination. In October 2016, we and Baxalta entered into a letter agreement extending the Letter Agreement Deadline to 5:00pm Eastern Time on October 21, 2016. Prior to the deadline, in October 2016, we entered into the Asset Return and Termination Agreement (the “Termination Agreement”) with Baxalta. Pursuant to the Termination Agreement, the Original License Agreement was terminated in its entirety (other than certain customary provisions that survive termination, including those pertaining to confidentiality and indemnification), the Original License Agreement has no further force or effect, and all rights and obligations of the Company and Baxalta under the Original License Agreement were terminated. For additional information relating to the Termination Agreement, see Part I, Item 2, “License Agreements and Milestone Activities - Shire”.

In October 2016, we announced that James A. Bianco, M.D. retired from his position as president and chief executive officer. At the request of the Board of Directors, Richard Love, a director of the Company since 2007, was appointed to serve as interim president and chief executive officer. In connection with Dr. Bianco’s separation, we recorded $5.6 million in severance related costs which were recorded in selling, general and administrative expenses in the Statement of Operations for the three and nine months ended September 30, 2016. Concurrently with Dr. Bianco’s separation, we entered into a Consulting Agreement, (the “Bianco Consulting Agreement”) and an Effective Date Option Agreement, (the “Bianco Effective Date Option Agreement”) with Dr. Bianco. The Bianco Consulting Agreement provides for exclusive consulting services from Dr. Bianco for 12 months following his separation for a total consulting fee of $0.5 million to be paid in two installments. The Bianco Effective Date Option Agreement granted Dr. Bianco a stock option award covering 6,539,290 shares of our common stock, with 4,539,290 of the shares subject to the option at a per share exercise price of $0.3743 and 2,000,000 of the shares subject to the option at a per share exercise price of $1.10. Each of Dr. Bianco’s outstanding stock options granted by us are fully vested and Dr. Bianco will generally have up to two years from the date of his separation to exercise his vested stock options.